Related Experiment Video
Updated: Oct 22, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.2K
Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
Siddh van Oost1, Debora M Meijer1, Marieke L Kuijjer1,2
1Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Biomedicines
|August 27, 2021
Summary
Sarcomas, a group of complex cancers, show limited response to immunotherapy due to low neoantigens. Genomic complexity in sarcomas may drive anti-tumor immunity, offering new therapeutic targets.
Area of Science:
- Oncology
- Cancer Immunology
- Genomics
Background:
- Sarcomas are heterogeneous cancers with poor treatment outcomes.
- Immunotherapy, particularly T cell checkpoint blockade, shows promise in other cancers but benefits few sarcoma patients.
- Limited neoantigens and T cell response are hypothesized reasons for immunotherapy resistance in sarcomas.
Purpose of the Study:
- To review the tumor microenvironment in sarcomas and its relationship with genomic features.
- To explore novel therapeutic strategies for enhancing sarcoma immunotherapy efficacy.
Main Methods:
- Literature review focusing on sarcoma genomics, tumor microenvironment, and immunotherapy.
- Analysis of genomic complexity and its potential role in immune cell infiltration.
- Discussion of emerging therapeutic approaches targeting the sarcoma tumor microenvironment.
Main Results:
- Sarcomas with complex genomes exhibit frequent chromosomal instability.
- Genomic events in complex sarcomas may contribute to immune responses.
- The tumor microenvironment and genomic landscape significantly influence immunotherapy outcomes.
Conclusions:
- Understanding sarcoma genomics and the tumor microenvironment is critical for improving immunotherapy.
- Targeting the tumor microenvironment presents a promising strategy to enhance clinical efficacy of immunotherapies for sarcomas.
- Novel therapeutic avenues are needed to overcome current challenges in sarcoma treatment.
Related Concept Videos
01:27Tumor Immunotherapy
771
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
771
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.3K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
8.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K